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Prophylactic oral anticoagulation in nephrotic patients with idiopathic
membranous nephropathy. Whether the high incidence of thromboem-
bolic events in nephrotic patients with membranous nephropathy justi-
fies prophylactic administration of oral anticoagulants remains contro-
versial. We used a Markov-based decision analysis model, explicitly
considering the consequences of recurrent embolic and bleeding events
to quantify the risk-benefit trade-offs of: (1) prophylactic therapy, in
which oral anticoagulation was started at the time of diagnosis of
nephrotic syndrome (before any thromboembolic event); and (2) anti-
coagulant therapy, in which treatment was started after the first clinical
thromboembolic event. We assumed that anticoagulant therapy was
discontinued if there was remission of the nephrotic syndrome. The
overall number of fatal emboli prevented by prophylactic anticoagu-
lants exceeded the one of fatal bleeding events for all clinically
meaningful ranges of the following parameters: nephrotic syndrome
duration, incidence of thromboembolic events, likelihood of emboliza-
tion, and mortality rates of embolic and bleeding events. For a
hypothetical 50-year-old patient who remained nephrotic for 2 years,
prophylactic anticoagulation yielded a gain representing 2.5 months of
quality-adjusted life expectancy. We conclude that for nephrotic pa-
tients with membranous nephropathy, the benefits of prophylactic
administration or oral anticoagulants outweigh the risks.
Thromboembolic phenomena, including deep venous throm-
bosis in the legs (DVT) and renal vein thrombosis (RVT), are an
ever-present danger for nephrotic patients, and remain a wor-
rying source of morbidity and mortality. Current recommenda-
tions are that once the diagnosis of acute thrombosis is estab-
lished, heparin is the initial therapy of choice, followed later by
oral anticoagulation [1—3]. Oral anticoagulant therapy should
probably be continued for as long as the patient remains
nephrotic, since the hypercoagulable state persists.
The numerous abnormalities of the coagulation and hemosta-
sis system in nephrotic patients have been reviewed extensively
[1, 2]. Briefly, these coagulation disorders may arise from two
distinct mechanisms, both related to glomerular injury: (1)
hyperpermeability with urinary loss of antithrombotic proteins,
such as antithrombin III, and hypoalbuminemia favoring plate-
let hyperactivity, alterations in the fibrinolytic system and
increased synthesis of procoagulant proteins; and (2) activation
of the glomerular hemostasis system with thrombin formation.
Since the incidence of thromboembolic events is so high in
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nephrotic patients with membranous nephropathy, whether
prophylactic oral anticoagulant therapy is justified remains
unanswered and is controversial in the literature. We have used
a Markov-based decision analysis model, explicitly considering
the consequences of recurrent embolic and bleeding events, to
examine the risks and benefits of oral anticoagulant therapy
started immediately after the first clinical thromboembolic
episode with a strategy of prophylactic oral anticoagulant
therapy.
Methods
Decision analysis is a technique for choosing among alternate
strategies [4, 5]. To analyze a decision, the strategies are
defined, subsequent important and plausible clinical events for
each strategy are described, and the probability of each event is
specified. A value (utility) is assigned to each state of health
considered, and the expected utility for each strategy is calcu-
lated. The strategy with the greatest expected utility is the
preferred choice. The structure of the analysis is described
below. The Appendix gives detailed explanations about the
model itself, the assumptions, the utilities, and the chance
events in the decision tree.
The decision model
To examine the question of prophylactic oral anticoagulation
in nephrotic patients, we developed a model that balances the
risks and benefits of long-term oral anticoagulation. The deci-
sion tree (Fig. 1) describes the choices and chances facing the
patient and physician. The square node at the left represents the
choice between the two strategies: (1) Observation, in which
oral anticoagulant therapy is started in patients having suffered
and survived a clinically apparent thromboembolic event, and
(2) Anticoagulation, in which anticoagulant therapy is started at
the time of diagnosis of nephrotic syndrome, before any clini-
cally apparent thromboembolic event (prophylactic therapy). In
both strategies, oral anticoagulant therapy is only administered
as long as patients remain nephrotic. If remission of the
nephrotic syndrome occurs, anticoagulation is discontinued.
We used a Markov state transition model represented by the
infinity sign to simulate recurrent chance events beyond the
patient and physician's control [6]. Recurrent chance events
(Fig. 1, B through D), represented by round nodes include age,
sex, race and membranous nephropathy-related mortality, as
well as embolic and bleeding events with their consequences
and related morbidities.
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OK off anticoagulation
Pulmonary
embolism
Fig. 1. The decision tree. The square node
(A) represents the choice between the two
strategies; Observation and Anticoagulation.
The figure is divided in four subtrees that
represent the initial decision and the Markov
states of health (A), complications from deep
venous thrombosis (B), complications from
renal vein thrombosis (C), and anticoagulation
complications (D).
Table I summarizes the rates and probabilities used in the
analysis. The range of estimates derived from literature
sources, and the baseline values used in our analysis are
included. Justifications for some data are given in the accom-
panying Appendix. Monthly transition probabilities were calcu-
lated for the Markov simulation from annual rates using the
formula: monthly probability = 1 — e(_hI rate x 1/12 years)
Review of relevant data
Thromboembolism in nephrotic patients. There has been
much controversy about the true incidence of renal vein throm-
bosis (RVT), and deep vein thrombosis in the legs (DVT) in
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580 Sarasin and SchUferli: Oral anticoagulants in nephrotic patients
Table 1. Rates and probabilities used in the analysis
Literature
Variable range Baseline
Rates percent/month
Thromboembolic events (patients with MGN)
DVT [1, 2, 7—11] 0.5—1.6 1.0
RVT[l,2,7—ll] 0,4—9 0.5
Anticoagulation
Major bleeding event [19—21] 0.06—1.8 0.25
MGN-related excess mortality [12] 0.2 0.2
Probabilities
Pulmonary embolism (untreated patients)
Following DVT [15, 16] 50% 50%
Following RVT [1, 2] 20—40% 30%
Death from pulmonary embolism [17, 18] 30% 30%
Death from major bleeding [21, 23] 9—15% 12%
Long-term sequelae from bleeding [23] 5% 5%
Efficacya
Anticoagulation [24] 60—80% 70%
Abbreviations are: MGN, membranous nephropathy; DVT, deep
venous thrombosis; RVT, renal vein thrombosis.
a (events in untreated pts — events in treated pts)/events in untreated
pts
nephrotic patients [7—91. Studies indicate an average prevalence
of approximately 35% for RVT with ranges in individual studies
from 5 to 60%, while the prevalence of thrombotic complica-
tions at other sites ranges from 8.5 to 44% [1—9]. The only point
above contention is that thrombosis is much more common in
patients with a nephrotic syndrome arising from idiopathic
membranous nephropathy (MGN), when compared to the inci-
dence in other varieties of nephrotic syndrome, including
membranoprolilerative glomerulonephritis, focal glomerulo-
sclerosis, and rapidly progressive glomerulonephntis (10—12].
Thromboses also seem to parallel the degree of hypoalbumin-
emia since thromboembolic events are more frequent in pa-
tients with low albumin level (<2 gIdl) [1, 2, 13, 141.
Table 2 shows the incidence of both clinically apparent and
silent thromboses (RVT and DVT) in two different nephrotic
populations: (I) nephrotic patients with membranous nephrop-
athy; and (2) patients with nephrotic syndrome of other types.
We used the studies for which time dependent data are available
to calculate the monthly incidence of RVT and DVT. In our
baseline analysis, we only considered the incidence of clinically
apparent thromboses, that is 0.5% per month for RVT and 1%
per month for DVT (Table 2). A critical overview of the
literature and justifications for the use of the data employed are
given in the Appendix.
Venous thrombosis and pulmonary embolism. In the setting
of renal vein thrombosis, the likelihood of embolization is
difficult to assess, as many RVT are clinically inapparent.
However, for Cameron, pulmonary embolism occurred in 20%
to 40% of untreated RVT (Appendix) [1].
The likelihood of embolization from deep venous thrombi
(DVT) is dependent upon anatomical location. Approximately
50% of untreated clinically apparent proximal deep venous
thrombi in the legs embolize to the lungs (Appendix) [15, 16].
Pulmonary embolism mortality. Pulmonary embolism (PE)
carries a high mortality rate. Ten percent of untreated patients
with massive PE die within the first hour. Of patients who
survive the acute event, clinical recognition and early treatment
are instituted in only 27%, resulting in a decreased mortality of
2.5 to 8% [17, 18]. The 73% who remain undiagnosed and
untreated remain at high risk for recurrent emboli and incur a
mortality of 32% from subsequent PEs (17].
Anticoagulation-related hemorrhagic complications. In re-
cent reviews of hemorrhagic complications of long-term oral
anticoagulant therapy, the rate of major bleeding complications
was shown to correlate with the intensity of anticoagulant
therapy and a number of predictive risk factors including
co-morbid conditions [19—21]. In the setting of hypoproteinemic
nephrotic patients, possible changes of the pharmacokinetics of
oral anticoagulants resulting in an increased risk of bleeding
events could occur. However, there are no data in the literature
studying this hypothesis. In our analysis, the baseline annual
risk of major bleeding events is 3% per year, or 0.25% event per
month (see Appendix for justifications).
Nine to fifteen percent of all major bleeding events were fatal
in Landefeld's study [20]. A similar fatality rate of 14% was
derived from a review of five studies of anticoagulant therapy
alter myocardial infarction [22]. Using data from the Sixty Plus
Reinfarction Study, the risk of major morbidity in survivors of
a major bleed was estimated to be 5.4% [23].
Efficacy of oral anticoagulation. Although some series sug-
gest clinical efficacy [3, 7], there are no reports in the literature
specifically examining the efficacy of oral anticoagulation in the
clinical setting of nephrotic patients. We used combined trials in
other clinical settings to assess the effectiveness of oral antico-
agulation in preventing venous thromboembolism [24]. Efficacy
was calculated as follows:
% events in untreated patients — % events in treated patients
% events in untreated patients
Using the above formula, oral anticoagulation was found to be
70% effective in preventing venous thromboembolism.
Death from natural causes and from membranous
nephropathy
The mortality related to patient's age, sex and race was
calculated from standard tables of vital statistics by taking the
reciprocal of the life expectancy [25]. The excess annual
mortality rate for membranous nephropathy was obtained from
data on the natural history of untreated patients [26]. The mean
age for patients with membranous nephropathy was 50 years
[24].
Results
Baseline analysis
Using the baseline probabilities and utilities defined in Table
1, prophylactic oral anticoagulation was the preferred strategy.
Specifically, the difference between the number of fatal pulmo-
nary embolic episodes prevented by prophylactic administra-
tion of anticoagulants and those prevented by anticoagulants
administered only after a thromboembolic event was balanced
against the number of fatal hemorrhages induced by prophylac-
tic anticoagulation. This relationship is depicted in Figure 2 for
a hypothetical cohort of 10,000 fifty-year-old nephrotic patients.
The overall number of fatal emboli prevented by the prophy-
lactic oral anticoagulant therapy exceeded the number of fatal
I 
—
-
 
Sarasin and Sch1ferli: Oral anticoagulants in nephrotic patients 581
Table 2. Frequency of venous thrombosis in adults with nephrotic syndrome
Abbreviations are: N, number of patients; MGN, membranous nephropathy
a Patients with nephrotic syndrome of all other types, excluding those with diabetic nephropathy
bleeding events for all ranges of nephrotic syndrome duration.
For the clinical scenario of a 50-year-old patient with membra-
nous nephropathy who remained nephrotic for two years,
prophylactic oral anticoagulation (Observation) yielded the
greatest quality-adjusted life expectancy (15.9 QALYs). This
represented an additional 2.5 months of quality-adjusted sur-
vival compared to the Observation strategy (15.7QALYs).
Sensitivity analysis
Sensitivity analysis provides a tool for addressing the uncer-
tainty of medical problems. By varying the probabilities and
utility values over a wide range, we can assess how such
variations might affect the ranking of strategies. Sensitivity
analyses were performed on all parameters in the model. The
subsequent analyses refer to 50-year-old patients with idio-
pathic membranous nephropathy, and who remained nephrotic
for two years.
Threshold I
Baseline
Rate of thromboembolic events. A one-way sensitivity anal-
ysis looks at the effect of varying a single variable while holding
all others constant. In Figure 3, quality-adjusted life years are
shown on the vertical axis as a function of the monthly rate of
venous thrombosis (DVT and RVT) on the horizontal axis.
Each line represents a different strategy. As the likelihood of
thromboembolic events (DVT and RVT) increases, the gain
provided by prophylactic oral anticoagulant therapy increases.
Each line in the graph represents the expected utility for a given
strategy. The threshold probability of venous thrombosis is
0.4% per month for proximal thrombosis in the legs and 0.2%
per month for renal vein thrombosis, less than half the baseline
value. Only below that threshold, the Observation strategy is
preferred over prophylactic Anticoagulation.
N studied
Total exposure time
(Pt-years) RVT/l00 Pt-month
Study MGN Othersa MON Othersa MON Othersa
A. Asymptomatic renal vein thrombosis (RVT)
Llach et al [7] 69 82 621 738 3.2 1.7
Wagoner et al [3] 27 — 144 — 9 —
Velasquez Forero et al [10] 5 21 165 693 1.8 1.1
Total 930 1431
Weighted average 3.8 1.4
B. Clinically apparent renal vein thrombosis (RVT)
Andrassy et al [9] 20 64 720 2304 0.5 0.08
Ardiles et al [11] 29 — 1218 — 0.4
Total 1938 2304
Weighted average 0.5 0.08
C. Clinically apparent proximal deep vein thrombosis in the legs (DVT)
Andrassy et al [9] 20 64 720 2304 0.5 0.13
Liach et al [7] 69 82 621 738 1.6 2.0
Total 1341 3042
Weighted average 1 0.6
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Fig. 2. Number of fatal embolic and major bleeding events for differ-
ent ranges of nephrotic syndrome duration. Symbols are: (0) fatal
bleed induced by prophylactic AC; (El) fatal PE prevented by prophy-
lactic AC.
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Monthly rate of thromboembolic events (RVT & DVT)
Fig. 3. One-way sensitivity analysis examining the monthly rate of
thromboembolic events, including deep venous thrombosis (DVT) and
renal vein thrombosis (RVT).
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Monthly rate of major bleeding events
Fig. 4. One-way sensitivity analysis examining the monthly rate of
major bleeding events.
Likelihood of embolization in patients with RVT and DVT. In
sensitivity analyses (results not shown) we tested the effect of
varying the baseline rate of pulmonary embolism (30%) in
untreated RVT. Observation became preferred over prophylac-
tic Anticoagulation only if the likelihood of embolization was
below 6%.
Risk of bleeding. Figure 4 represents a one-way sensitivity
analysis of the monthly risk of bleeding. Prophylactic anticoag-
ulant therapy (Anticoagulation) remained the preferred strategy
unless the monthly risk of major bleeding events was over 0.6%
per month (7% per year), considerably more than the baseline
value of 0.25%.
In addition to a one-way sensitivity analysis, the effect of
varying two or three parameters simultaneously could be as-
sessed. These sensitivity analyses were called, respectively,
two-way and three-way sensitivity analysis. Figure 5 is a
three-way sensitivity analysis in which the horizontal axis
represents the rate of pulmonary embolism given the presence
of an acute DVT or RVT, while the vertical axis represents the
rate of bleeding events. The two curves describe threshold
regions for two different efficacy rates associated with antico-
agulant therapy. In the region towards the upper left, the
Observation strategy is preferred, while Anticoagulation is
optimal in the region towards the lower right. For all values
falling below any line, Anticoagulation is preferred. At the
baseline values, Anticoagulation is preferred. As the efficacy of
anticoagulant therapy decreases, the region in which Anticoag-
ulation is preferred becomes smaller.
Although clinical data on the incidence of venous thrombosis
in this population are lacking, we also extended our analysis to
study the clinical scenario of patients with other varieties of
nephrotic syndrome. In this clinical setting, where the inci-
dence of thromboembolic events seemed to be lower (Table 2),
prophylactic oral anticoagulation (Anticoagulation) remained
the preferred strategy, still providing a small benefit compared
to the Observation strategy. However, sensitivity analyses
performed on key variables (that is, risk of major bleeding
events, likelihood of pulmonary embolism given acute throm-
bosis), affected the ranking of strategies, and the benefits
provided by the administration of prophylactic anticoagulants
were outweighted by the risks.
DIscussion
Literature indicates that among nephrotic patients, the inci-
dence of thromboses is much more common among those with
idiopathic membranous nephropathy compared to those with
nephrotic syndrome of any other variety. In spite of this risk,
oral anticoagulant therapy traditionally has been confined to
patients with diagnosed acute thrombosis or in survivors of an
acute pulmonary embolic event, with some authors warning
that the risk of thrombosis is not sufficient to justify the risk of
prophylactic oral anticoagulation. Our model suggests that
prophylactic oral anticoagulation administered while patients
remain nephrotic increases life expectancy, and that the benefit
provided by its efficacy in preventing pulmonary embolization
outweights its risks. This result extends to a wide range of
nephrotic syndrome duration, and neither age, nor gender affect
this benefit.
The literature is controversial about the incidence of renal
vein thrombosis, deep vein thrombosis in the legs, and the
likelihood of pulmonary embolism in patients with established
RVT. However, we performed multiple sensitivity analyses
(Figs. 3—5) on these "key" clinical parameters. Our results
revealed that for observation to be preferred over prophylactic
anticoagulation, the monthly rate of venous thrombosis would
have to be more than two times lower than our baseline value
(Fig. 3), and the monthly rate of bleeding events would have to
exceed that of our baseline analysis by a factor of two (Fig. 4).
Furthermore, for patients with established RVT, the likelihood
of pulmonary embolism has to be below 6%, much less than all
estimates found in the literature, for Observation to be pre-
ferred over prophylactic oral Anticoagulation.
Prophylactic anticoagulation remains the preferred strategy,
although we deliberately biased our analysis against this strat-
egy. First, the prevalence of RVT varied according to whether
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Fig. 5. Three-way sensitivity analysis eximining the likelihood of pul-
monary embolism given DVT and RVT, the monthly rate of major
bleeding events, and two dUferent bleeding rates associated with
anticoagulant therapy.
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a clinical or a venographic diagnosis was considered (Table 2);
the latter showed a much higher prevalence. In our analysis, we
reduced the incidence of RVT to that of symptomatic RVT
which widely underestimated the benefit prophylactic anticoag-
ulation provided in also preventing embolization due to asymp-
tomatic RVT (Appendix). Secondly, our estimated bleeding rate
(3% per year) corresponded to the risk of patients with one or
two risk factors for bleeding [20, 21] (Appendix) and repre-
sented an "upper range" estimate.
Interpretation and evaluation of an analysis such as this
involve assessment of the fidelity of the model. Does our
model's structure adequately represent the complexity of the
clinical problem? First, the occurrence of well-recognized
thromboembolic complications other than venous thromboses
including arterial thrombosis (axillary, femoral, ophtalmic, ca-
rotid), and unusual localization of venous thrombosis (mesen-
teric, portal, subclavian vein) [27—29] was not represented.
Secondly, the occurrence of renal complications following
acute renal vein thrombosis (flank pain, hematuria, deteriora-
tion in renal function) was not represented either. However,
exluding these events from our model added another bias
against prophylactic administration of anticoagulants which
strengthened our result. Indeed, oral anticoagulation will un-
doubtedly provide some degree of protection against these
complications, thus increasing the benefit provided by its pro-
phylactic administration.
For nephrotic patients with other types of nephropathy
(membranoproliferative and rapidly progressive glomerulone-
phritis, focal glomerulosclerosis), much uncertainty surrounds
the incidence of thromboembolic phenomena; however, it
seems undoubtedly lower. Excluding patients with diabetic
nephropathy alone or in addition to other nephropathy because
of the presence of multiple comorbidities, like retinopathy or
hypertension which could affect the conclusions, we also stud-
ied the consequences of prophylactic oral anticoagulants in this
population. In this setting, our baseline analysis shows that
prophylactic oral anticoagulation still provides a small gain over
observation for all ranges of nephrotic syndrome duration.
However, compared to the scenario of patients with idiopathic
membranous nephropathy small variations on key parameters
influence the outcome and the ranking of the strategies. In this
clinical setting where thrombosis is less common compared to
patients with membranous nephropathy, the number of fatal
pulmonary emboli prevented by prophylactic anticoagulants is
easily overwhelmed by the risk of major bleeding complica-
tions. In such clinical situations, where the gain between the
two strategies is not significant and the analysis is very sensitive
to many of the key parameters, the optimal therapeutic decision
becomes a toss-up [30].
Decision about choices of prophylactic anticoagulation for
nephrotic patients with MGN involves consideration of many
complex variables, including the risk of DVT and/or RVT, the
likelihood of embolization, and the risk of bleeding. Our model
handles this complexity and suggests that the extremely high
rate of thromboembolic events justifies the use of prophylactic
anticoagulation. However, a model like this one may not be
sufficient to recommend uniformly prophylactic oral anticoag-
ulation in nephrotic patients with MGN. Decision analysis
models do not replace the need for prospective randomized
clinical trials. Hence, in addition to suggesting that in the setting
of nephrotic patients with MGN the benefits of oral anticoagu-
lation outweigh the risks, the results of the present study should
prompt a large multicentric prospective clinical trial to quantify
more precisely the incidence of thromboembolic events and
evaluate the consequences of oral anticoagulation.
Reprint requests to Fran cois Sarasin, M.D., Clinique Médicale 1,
Hôpital Cantonal Universitaire, 24 rue Micheli du Crest, 12/1 Geneva
14, Switzerland.
Appendix A: The decision tree
This appendix contains detailed explanations of: (1) the assumptions
we made in formulating this analysis; (2) the Markov models; and (3) the
assignment of utilities.
Assumptions
In formulating our model, we made a number of simplifying assump-
tions.
(1.) Anticoagulant therapy is administered as long as patients remain
nephrotic. If remission of the nephrotic syndrome occurs, anticoagulant
therapy is discontinued.
(2.) Nephrotic syndrome arising in children or in patients with
diabetic nephropathy were excluded from our analysis.
(3.) The risk of major bleeding events is constant while patients
receive anticoagulant therapy.(4.) Patients who suffer a non-fatal hemorrhage while receiving
anticoagulant therapy discontinue the drug for one month, then resume
anticoagulant therapy.(5.) The short-term morbidity from a pulmonary embolism is more
severe than the short-term morbidities from systemic hemorrhage or
acute thrombosis (DVT or RVT). Patients who experience two of these
events in the same cycle are assigned the quality adjustment for the
more severe.
(6.) We did not model long-term morbidity from recurrent pulmonary
embolism (such as pulmonary hypertension, right-sided heart failure).
(7.) Patients sustaining long-term morbidity from an event are still
subject to the risks of future events.
Markov models
In a Markov process, patients in a hypothetical cohort are exposed to
the same set of chance events repetitively over time. The passage of
time is divided into intervals called cycles; in each monthly cycle,
recurrent chance events (such as hemorrhage, embolism) may lead to a
transition to a different state of health. The simulation ultimately
calculates the average life expectancy of the cohort [6]. The Markov
model is represented by a rectangular node with circles connected by an
arrow (Fig. 1A). Patient's states of health are shown as branches
emanating from the Markov node.
Patients begin the Markov process in different states depending on
the strategy chosen. In the Observation strategy, patients begin in the
state OK off Anticoagulation, whereas in the Anticoagulation strategy,
they begin in the state OK on Anticoagulation. Patients remain in the
same state for ensuing cycles unless they experience one or more
adverse events, represented by a cascaded set of subtrees (Fig. 1B-D).
During each cycle, patients may die of other causes, including age, sex,
race, and membranous nephropathy-related excess mortality (moving
to the Dead state). If they survive, they may develop Deep Venous
Thrombosis and/or Renal Vein Thrombosis, which may lead to Pulmo-
nary Embolism. Pulmonary Embolism may be fatal. Survivors of
pulmonary embolism as well as patients with renal and/or deep venous
thrombosis then face the complications of anticoagulant therapy. Pa-
tients receiving anticoagulant therapy immediately (Anticoagulation
strategy) may also suffer from bleeding events. Bleeding may be fatal,
or may lead to major (that is, long-term), or minor (that is, short-term)
morbidity.
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Table 3. Quality of life adjustment factors (QAFs) used in the
baseline analysis
State of health QAF
Long-term morbidity
Systemic hemorrhage 0.5
Short-term morbidity
Systemic hemorrhage 0.7
Pulmonary embolism 0.6
Renal vein thrombosis 0.8
Deep vein thrombosis 0.8
Assignment of utilities
In this analysis, the outcome of each strategy is measured (1) by
calculating the number of fatal complications from embolic and major
bleeding events for a hypothetical cohort of 10,000 nephrotic patients;
and (2) in terms of quality-adjusted life years (QALYs) [31]. This scale
addresses both longevity and quality of life (utility). As life expectancy
is calculated by the Markov process, it is adjusted for the loss of quality
experienced by the patient with each strategy. Quality of life is
diminished by reduced functional capabilities in both the short- and
long-term. A month spent in the patient's baseline state of health is
assigned one full quality-adjusted month, and months in which the
patient has morbidity (such as hemiplegia or pulmonary embolism) are
given values between zero and one. Table 3 lists the baseline short-term
and long-term quality-of-life adjustments used in the analysis.
Appendix B: Explanations and justification for the data used in
the baseline analysis
Incidence of renal vein thrombosis (RVT) in nephrotic
patients
Studies on RVT in nephrotic patients indicate an average prevalence
of 35%. However, in individual studies this number ranges from 5% to
60% [1—3, 7—11]. Several reasons explain this wide range. First, it has
been shown that thromboembolic events are more frequent in associa-
tion with idiopathic membranous nephropathy [1—3, 7—11]. Thus, in
studies including all types of nephrotic patients, the incidence of RVT
is probably underestimated when compared to patients with membra-
nous nephropathy, while it is overestimated compared to patients with
other types of glomerular diseases.
Secondly, the intensity of hypercoagulability among nephrotic pa-
tients seems to correlate the degree of hypoalbuminemia, since throm-
boses are particularly frequent at plasma albumin concentrations below
2 gldl [1—3, 7—Il]. Thus, studies including heterogeneous groups of
nephrotic patients with different plasma albumin concentrations may
underestimate the incidence of thromboembolic events when compared
to patients with low plasma albumin, and overestimate the incidence
when compared to patients with normal plasma albumin levels.
Third, experience in the evaluation of patients with RVT demon-
strated the presence of two different modes of clinical presentation:
acute and chronic [7]. Acute RVT is characterized by flank pain,
hematuria, and deterioration of renal function while chronic RVT is
usually asymptomatic [7]. Thus, in studies where nephrotic patients
were prospectively and systematically evaluated for the presence of
RVT with intravenous pyelogram and inferior vena cavagram the
incidence of RVT was high, between 1.8% and 9% per month [6, 7, 10]
(Table 2A). On the other hand, in studies where only symptomatic
patients underwent a radiologic diagnostic procedure the incidence of
clinically apparent RVT was much lower, around 0.5% per month
(Table 2B)[9, 11].
We used the studies for which time-dependent data are available to
calculate the monthly incidence of RVT. When data on the mean
follow-up period were lacking, we used the maximum follow-up obser-
vation. However, this assumption creates an underestimation of the
real incidence of RVT in nephrotic patients. In our analysis, we chose
a baseline value of 0,5% per month for the incidence of RVT, corre-
sponding to the incidence of clinically apparent RVT. By omitting silent
RVT, this baseline value underestimates the real incidence of RVT and
deliberately biases our model in favor of the Observation strategy.
Incidence of deep venous thrombosis (DVT) in nephrotic
patients
Series studying the incidence of deep venous thrombosis in the lower
limbs are shown in Table 2C. For patients with membranous nephrop-
athy, the incidence of DVT ranges between 0.5% and 1.6% per month
[9]. This represents a relative risk of at least 50, when compared to a 60-
to 70-year-old hospitalized population where the incidence of deep
venous thrombosis is 0.01% per month [32]. In our baseline analysis, we
used a baseline value of 1% per month for the incidence of acute DVT,
which is a weighted average from the two studies mentioned above.
Only the occurrence of proximal (thigh) acute venous thrombosis was
considered.
In the setting of nephrotic syndrome of other types, the incidence of
venous thrombosis in the extremities ranges between 0.13 and 2% per
month [7, 9].
Likelihood of embolization in patients with RVT
The likelihood of pulmonary embolism in patients with RVT is
difficult to assess. Specifically, whether the clinically inapparent RVT
are associated with a high incidence of pulmonary emboli remains
unanswered. Cameron carefully summarized the available data on the
frequency of pulmonary embolism in the particular clinical setting of
RVT [1]. In his review, the incidence of pulmonary embolism ranged
from 10% to 60% depending on the diagnostic technique. However,
since no pulmonary angiography was done in these patients, a definite
interpretation of these findings is not possible.
In our baseline analysis we used an expert's estimate of the incidence
of pulmonary embolization in patients with RVT: 30% of patients with
untreated RVT will develop pulmonary embolism [1].
Likelihood of embolization in patients with DVT in the legs
The likelihood of pulmonary embolism is dependent upon anatomical
location, and not the clinical setting in which the thrombosis occurs.
Thus, 50% of untreated acute proximal venous thrombosis in the legs
will embolize to the lungs [15, 16].
Anticoagulation-related hemorrhagic complications
In reviews of major hemorrhagic complications of oral anticoagulant
therapy, major bleeds included intracranial and retroperitoneal hemor-
rhage as well as those which resulted in hospitalization, transfusions or
death [19—21]. By analyzing risk factors known at the start of therapy,
Landefeld et al developed a method for estimating the risk of major
bleeding in patients receiving long-term anticoagulant therapy [20, 211.
Five independent risks factors [(1) age 65 or older; (2) history of stroke;
(3) history of gastrointestinal bleeding; (4) serious comorbid condition
including recent myocardial infarction, renal insufficiency, liver failure,
or cancer, and (5) atrial fibrillation] were predictive of major bleeding
events. For the high risk patient with three or more risk factors, the
cumulative incidence of major bleeding was 17% per year, or 1.4% per
patient-month. In comparison, middle risk patients with one or two risk
factors had an annual incidence of major bleeding averaging 3% per
year, or 0.25% per patient-month. In low risk patients with no risk
factors, the annual incidence of major bleeding events is 0.5%, or less
than 0.05% per patient-month.
In our baseline analysis, the risk of major bleeding events corre-
sponded to the bleeding risk of patients with one or two risk factors (3%
per year or 0.25% per patient-month).
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